Therapeutic genome editing: regulatory horizons

Philip A. Hines; Eleonora Agricola; Jordi Llinares Garcia; Laurence O'Dwyer; Ralf Herold

doi:10.1038/d41573-021-00130-7

Therapeutic genome editing: regulatory horizons

Philip A. Hines^*, Eleonora Agricola, Jordi Llinares Garcia, Laurence O'Dwyer, Ralf Herold

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

An increasing number of genome-editing technologies are being developed. Here, we highlight some of the key issues for future therapies using these technologies from a regulatory perspective.

Original language	English
Pages (from-to)	1-2
Number of pages	2
Journal	Nature Reviews Drug Discovery
Volume	21
Issue number	1
DOIs	https://doi.org/10.1038/d41573-021-00130-7
Publication status	Published - 1 Jan 2022

Access to Document

10.1038/d41573-021-00130-7

Cite this

@article{7de725bbc890493d8070eeaa168e35a5,

title = "Therapeutic genome editing: regulatory horizons",

abstract = "An increasing number of genome-editing technologies are being developed. Here, we highlight some of the key issues for future therapies using these technologies from a regulatory perspective.",

author = "Hines, {Philip A.} and Eleonora Agricola and {Llinares Garcia}, Jordi and Laurence O'Dwyer and Ralf Herold",

year = "2022",

month = jan,

day = "1",

doi = "10.1038/d41573-021-00130-7",

language = "English",

volume = "21",

pages = "1--2",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Therapeutic genome editing

T2 - regulatory horizons

AU - Hines, Philip A.

AU - Agricola, Eleonora

AU - Llinares Garcia, Jordi

AU - O'Dwyer, Laurence

AU - Herold, Ralf

PY - 2022/1/1

Y1 - 2022/1/1

N2 - An increasing number of genome-editing technologies are being developed. Here, we highlight some of the key issues for future therapies using these technologies from a regulatory perspective.

AB - An increasing number of genome-editing technologies are being developed. Here, we highlight some of the key issues for future therapies using these technologies from a regulatory perspective.

U2 - 10.1038/d41573-021-00130-7

DO - 10.1038/d41573-021-00130-7

M3 - Comment/Letter to the editor

SN - 1474-1776

VL - 21

SP - 1

EP - 2

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 1

ER -

Therapeutic genome editing: regulatory horizons

Abstract

Access to Document

Fingerprint

Cite this